Pfizer's secret deal with the government: will Washington or shareholders profit more from it?
Pfizer promised America cheaper drugs and got three years of tariff peace in return. But the released contract shows Washington took a cut of its foreign sales. What does that mean for the dividend above 6%, which millions of people hold the stock for?
Key points
The text of Pfizer's agreement with the White House only came to light after a consumer organization's lawsuit
The contract contains a foreign sales clause, whose key figures remain redacted
Pfizer lowered Eliquis's list price, yet its US sales from the drug rose 25%
The dividend yield above 6% rests on a balance sheet that management itself won't improve for three years
Pfizer's political protection expires on January 20, 2029, the year the company expects to return to growth
A contract that had to be pried loose by a consumer group
When Pfizer $PFE signed a drug pricing agreement at the White House on September 30, 2025, it was sold as a clear deal: the company would lower prices for American patients and in return get a three-year exemption from pharmaceutical tariffs. But what exactly it signed remained unseen for almost a year. The government released the text only after a Freedom of Information lawsuit by the consumer group Public Citizen on September 19, 2026.
The document changes the whole story. According to Public Citizen's analysis, last September's signing was just a letter of intent; the definitive contract was signed on February 23, 2026. And it contains a clause that wasn't mentioned at press conferences: Pfizer will give the Department of Health and Human Services (HHS) a share of the net sales increase it gains from higher prices for its already-sold drugs abroad. The provision runs from January 1, 2026, to January 20, 2029.
What percentage, for which drugs, and under what conditions Pfizer can terminate the contract immediately remains redacted. Of the 27 companies that signed similar deals with the government, only two texts are public: Pfizer and Eli Lilly. For Lilly, the foreign sales sharing section is fully blacked out.